Risks of combining immunosuppressive and biological treatments in inflammatory bowel disease

Arch Intern Med. 2008 Mar 24;168(6):667; author reply 667-8. doi: 10.1001/archinte.168.6.667.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunologic Factors / therapeutic use*
  • Immunosuppressive Agents / therapeutic use*
  • Inflammatory Bowel Diseases / drug therapy*
  • Infliximab
  • Male
  • Methotrexate / therapeutic use*
  • Risk Factors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Immunologic Factors
  • Immunosuppressive Agents
  • Infliximab
  • Methotrexate